The philosophy of Graves' ophthalmopathy

Orbit

Volumn 24, Issue 3, 2005, Pages 165-171

  Wiersinga, Wilmar M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Graves' disease; Hyperthyroidism; Smoking; Thyroid associated ophthalmopathy

Indexed keywords

ANTIOXIDANT; ANTITHYROID AGENT; IMMUNOSUPPRESSIVE AGENT; IODINE 131; PLACEBO; PREDNISONE; SELENIUM;

CLINICAL RESEARCH; CONFERENCE PAPER; ENDOCRINE OPHTHALMOPATHY; HORMONE DEFICIENCY; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; PATIENT CARE; PHILOSOPHY; PHYSICIAN; QUALITY OF LIFE; SMOKING; SUPPORT GROUP;

EYE DISEASES; GRAVES DISEASE; HUMANS; PATIENT CARE TEAM; PATIENT PARTICIPATION; SMOKING;

EID: 24144467743     PISSN: 01676830     EISSN: None     Source Type: Journal    
DOI: 10.1080/01676830500192167     Document Type: Conference Paper

References (28)

1. Aniszewski JP, et al. Relationship between disease duration and predominant orbital T-cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2000;83:776-780.
2. Bartalena L, et al. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med. 1998c;129:632-635.
3. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Eng J Med. 1998a;338:73-78.
4. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med. 1998b;129:632-635.
5. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168-199.
6. Bartley GB, Fatourechi V, Kadrmas EF. Long-term follow-up of Graves' Ophthalmopathy in an incidence cohort. Ophthalmology. 1996;103:958-962.
7. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 1995;120:511-517.
8. Gärtner RG, Gasnier BCH, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87:1687-1791.
9. Glinoer D, et al. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs. Eur J Endocrinol. 2001;144:475-483.
10. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001;108:1523-1534.
11. Perros P, Anwar A, Toft AD. Evidence for a decline in the incidence and severity of thyroid-associated ophthalmopathy: 20 year experience of a large thyroid clinic. J Endocrinol. 1996;148(Suppl.): 235.
12. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol. 1996;45:477-481.
13. Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003;148:491-495.
14. Prummel MF, Mourits MPh, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989;321:1353-1359.
15. Prummel MF, Mourits MPh, Blank L, et al. Randomized double-blind trial of prednisone verus radiotherapy in Graves' ophthalmopathy. Lancet. 1993;342:949-954.
16. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15-20.
17. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. J Am Med Assoc. 1993;269:479-482.
18. Prummel MF, Wiersinga WM, Mourits MPh, et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med. 1990;150:1098-1101.
19. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992;326:1733-1738.
20. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol. 2001;54:391-398.
21. Terwee CB, Gerding MN, Dekker FW, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol. 1999;52:875-884.
22. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773-779.
23. Terwee CB, Wakelkamp I, Tan S, et al. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751-757.
24. Wakelkamp IMMJ, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol. 2003;58:280-287.
25. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol. 1998;49:21-28.
26. Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med. 1998;338:121-122.
27. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12:855-860.
28. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Edocrinol Metab. 2002;13:280-287.